On October 22, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported it will host a conference call and webcast on Sat., Oct. 24 at 11:00 a.m. ET to discuss its presentations at the 2020 EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Virtual Symposium, including initial clinical data from the dose finding portion of the Phase 1 SHIELD-1 study of drug candidate, TPX-0022, a potent inhibitor of MET and the associated cancer signaling pathways of SRC and CSF1R (Press release, Turning Point Therapeutics, OCT 22, 2020, https://ir.tptherapeutics.com/news-releases/news-release-details/turning-point-therapeutics-host-conference-call-discuss [SID1234568850]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
President and CEO Athena Countouriotis, M.D., will host the webcast and conference call, and will be joined by Turning Point Chief Medical Officer, Mohammad Hirmand, M.D., and David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center.
The audio webcast and accompanying slide presentation will be accessible via the "Investors" section of www.tptherapeutics.com or audio only by dialing (877) 388-2118 (in the United States) or (470) 495-9489 (outside the U.S.) using conference ID 8655648. A replay will be available through the "Investors" section of www.tptherapeutics.com.
The TPX-0022 data are scheduled to be presented earlier that day by Dr. Hong in a late-breaking oral presentation during the plenary session of the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) (Free AACR Whitepaper).
Late-Breaking Presentation Details:
Presentation Title: First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
Session Title: Plenary Session 1, Late Breaking and Best Proffered Papers
Presentation Date (Time): Saturday, 24 October 2020 (16:05 – 16:15 CET/10:05 a.m. ET-10:15 a.m. ET)
Presenter: David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
Presentation Number: 1LBA